Renovacor

Philadelphia, United States Founded: 2013 • Age: 13 yrs Acquired By Rocket Pharma
BAG3-related gene therapies for cardiovascular and CNS disorders are developed.
Request Access

About Renovacor

Renovacor is a company based in Philadelphia (United States) founded in 2013 by Arthur Feldman was acquired by Rocket Pharma in September 2022.. Renovacor has raised $11 million across 1 funding round from investors including Rocket Pharma, New Leaf Venture Partners and Novartis Venture Fund. Renovacor operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.

  • Headquarter Philadelphia, United States
  • Founders Arthur Feldman
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
    $-780.77 K
    -150048
    as on Dec 31, 2020
  • EBITDA
    $-801.96 K
    -154123
    as on Dec 31, 2020
  • Total Equity Funding
    $11 M (USD)

    in 1 rounds

  • Latest Funding Round
    $11 M (USD), Series A

    Aug 14, 2019

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Rocket Pharma

    (Sep 20, 2022)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of Renovacor
Headcount 1-10
Employee Profiles 10
Board Members and Advisors 13
Employee Profiles
People
Valerie Myers
Senior Director, Preclinical Development
People
Jordan Shin
SVP, Clinical Development & Translational Science
People
Beth White
Chief Business Officer & SVP, Operations
People
Matt Killeen
Chief Scientific Officer

Unlock access to complete

Board Members and Advisors
people
Richard Peluso
Scientific Advisor
people
Jonas Grossman
Director
people
Gregory F. Covino
Director
people
Joan Lau
Director

Unlock access to complete

Funding Insights of Renovacor

Renovacor has successfully raised a total of $11M through 1 strategic funding round. The most recent funding activity was a Series A round of $11 million completed in August 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series A — $11.0M
  • First Round

    (14 Aug 2019)

  • Investors Count 5
Date Amount Transaction Name Valuation Lead Investors Investors
Aug, 2019 Amount Series A - Renovacor Valuation Novartis Venture Fund , Broadview Ventures
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Renovacor

Renovacor has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include Rocket Pharma, New Leaf Venture Partners and Novartis Venture Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Investments are made in innovative life science companies globally.
Founded Year Domain Location
Seed-stage life sciences investments are made in the US.
Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Renovacor

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Renovacor

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Renovacor Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Renovacor

Renovacor operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Drugs for CNS disorders are developed and advanced.
domain founded_year HQ Location
Developer of therapeutic solutions for the treatment of diabetes
domain founded_year HQ Location
Genetically engineered cell therapies are developed for multiple disorders.
domain founded_year HQ Location
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
domain founded_year HQ Location
Therapies for neurological and neuropsychiatric diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Renovacor

Frequently Asked Questions about Renovacor

When was Renovacor founded?

Renovacor was founded in 2013 and raised its 1st funding round 6 years after it was founded.

Where is Renovacor located?

Renovacor is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.

Who is the current CEO of Renovacor?

Magdalene Cook is the current CEO of Renovacor.

Is Renovacor a funded company?

Renovacor is a funded company, having raised a total of $11M across 1 funding round to date. The company's 1st funding round was a Series A of $11M, raised on Aug 14, 2019.

What does Renovacor do?

Renovacor was founded in 2013 in Philadelphia, United States, within the biotechnology sector. Emphasis is placed on drug development for cardiovascular and central nervous system disorders. BAG3-related gene therapies are pursued, including the candidate molecule REN-001, which remains in preclinical and research stages for cardiomyopathy and CNS indications. Operations center on advancing these therapies toward clinical applications.

Who are the top competitors of Renovacor?

Renovacor's top competitors include Jazz Pharmaceuticals, Neurocrine and Biohaven Pharmaceutical.

Who are Renovacor's investors?

Renovacor has 6 investors. Key investors include Rocket Pharma, New Leaf Venture Partners, Novartis Venture Fund, Broadview Ventures, and BioAdvance.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available